Download
s00404-020-05771-4.pdf 631,05KB
WeightNameValue
1000 Titel
  • First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
1000 Autor/in
  1. Ettl, Johannes |
  2. Anders, Sophie-Isabelle |
  3. Hapfelmeier, Alexander |
  4. Paepke, Stefan |
  5. Noske, Aurelia |
  6. Weichert, Wilko |
  7. Klein, Evelyn |
  8. Kiechle, Marion |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-09
1000 Erschienen in
1000 Quellenangabe
  • 302(6):1461-1467
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00404-020-05771-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584549/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Prospectively collected outcome data of patients (pts) whose adjuvant systemic therapy recommendation was based on the clinico-molecular test EndoPredict!##!Methods!#!Pts with ER-positive, HER2-negative early breast cancer with 0-3 positive lymph nodes were enrolled. The EP was carried out on all tumor samples. Pts were evaluated for treatment compliance, local recurrence, distant metastases and overall survival. Censored time-to-event outcomes were analysed by Cox proportional hazards models. Additional estimates of the event-free-survival were calculated by the Kaplan-Meier method. Hypothesis testing was conducted on two-sided exploratory 5% significance levels.!##!Results!#!373 consecutive pts were enrolled. EP classified 238 pts (63.8%) as low risk and 135 pts (36.2%) as high risk. Median follow-up was 41.6 months. Risk for disease recurrence or death in EPclin high-risk patients was twofold higher in comparison with EPclin low-risk patients (hazard ratio (HR) 2.05 (95% CI 0.85-4.96; p = 0.110). Patients with EPclin high risk were at significant higher risk of distant metastases than patients with EPclin low risk (HR 5.18; 95% CI 1.04-25.74; p = 0.0443). EPclin high-risk patients who actually underwent adjuvant CTX had a 3-year-DFS of 96.3% (95% CI 92.2-100) in contrast to EPclin high-risk patients without CTX (3-year-DFS: 91.5% (95% CI 82.7-100%); HR 0.32; 95% CI 0.10-1.05; p = 0.061).!##!Conclusion!#!These first prospective outcome results show that EP, in clinical routine, is a valid clinico-molecular test, to predict DFS and to guide decision of adjuvant CTX use in ER-positive, HER2-negative early breast cancer pts with 0-3 positive lymph nodes. Adjuvant CTX seems to be beneficial for EPclin high-risk patients.
1000 Sacherschließung
lokal Endopredict
lokal Aged [MeSH]
lokal Receptor, ErbB-2/metabolism [MeSH]
lokal Adjuvant chemotherapy
lokal Breast cancer
lokal Proportional Hazards Models [MeSH]
lokal Endocrine therapy
lokal Breast Neoplasms/mortality [MeSH]
lokal Female [MeSH]
lokal Receptors, Estrogen/metabolism [MeSH]
lokal Adult [MeSH]
lokal Kaplan-Meier Estimate [MeSH]
lokal Humans [MeSH]
lokal Prognostic biomarker
lokal Prospective Studies [MeSH]
lokal Treatment Outcome [MeSH]
lokal Breast Neoplasms/drug therapy [MeSH]
lokal Predictive Value of Tests [MeSH]
lokal Breast Neoplasms/metabolism [MeSH]
lokal Middle Aged [MeSH]
lokal Predictive biomarker
lokal Family Characteristics [MeSH]
lokal Chemotherapy, Adjuvant [MeSH]
lokal Disease-Free Survival [MeSH]
lokal Prognosis [MeSH]
lokal Antineoplastic Agents, Hormonal/therapeutic use [MeSH]
lokal Neoplasm Recurrence, Local/drug therapy [MeSH]
lokal Gynecologic Oncology
lokal Real-Time Polymerase Chain Reaction [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-4754-8447|https://frl.publisso.de/adhoc/uri/QW5kZXJzLCBTb3BoaWUtSXNhYmVsbGU=|https://frl.publisso.de/adhoc/uri/SGFwZmVsbWVpZXIsIEFsZXhhbmRlcg==|https://frl.publisso.de/adhoc/uri/UGFlcGtlLCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/Tm9za2UsIEF1cmVsaWE=|https://frl.publisso.de/adhoc/uri/V2VpY2hlcnQsIFdpbGtv|https://frl.publisso.de/adhoc/uri/S2xlaW4sIEV2ZWx5bg==|https://frl.publisso.de/adhoc/uri/S2llY2hsZSwgTWFyaW9u
1000 Hinweis
  • DeepGreen-ID: 43d25cff814341c6a618a001bd902fac ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6466680.rdf
1000 Erstellt am 2023-11-17T01:24:47.622+0100
1000 Erstellt von 322
1000 beschreibt frl:6466680
1000 Zuletzt bearbeitet Fri Dec 01 04:40:49 CET 2023
1000 Objekt bearb. Fri Dec 01 04:40:49 CET 2023
1000 Vgl. frl:6466680
1000 Oai Id
  1. oai:frl.publisso.de:frl:6466680 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source